In prostate cancer, however, CD8+ T-cell activity is frequently inhibited by immunosuppressive cells such as Tregs and MDSCs, as well as the expression of immune checkpoint molecules (e.g., PD-1/PD-L1) within the TME [36,60]. Here, CD8A is linked to prostate carcinoma.